Fig. 5.
Effects of TKi on the expression of stem cell–related genes in CML cell lines. Cells (3 × 105/mL) were treated with DMSO (CON), 2 μM imatinib (IM) or 8 nM ponatinib (PON) at time 0 and incubated for 24 h and c-MYC (a), NANOG, SOX2, and OCT4 (b) mRNA were measured by Q-PCR. Data were normalized with respect to the mean of GAPDH and β-actin mRNA levels and expressed as fold-change with respect to the values obtained for CON samples. Values represent mean ± SEM of three independent experiments, each carried out in triplicate. *p < 0.05; CML chronic myeloid leukemia, DMSO dimethyl-sulfoxide, GAPDH glyceraldehyde 3-phosphate dehydrogenase, Q-PCR quantitative polymerase chain reaction, SEM standard error of the mean, TKi tyrosine kinase inhibitors